FDA approves at least 3 drugs delayed under Makary in 2026

The FDA faces pressure from health care investors and lobbyists to reverse Makary’s unpredictable drug rejections. A successor will prioritize streamlining clinical trials and approvals to address these complaints.

Implied probability (Yes)

75%